Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve ...

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved ...

Shattuck Labs (STTK – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Joseph Pantginis today. The ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...

We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...

Immune checkpoint inhibitors industry is projected to witness a CAGR of 16.7% during the period 2024-2032. This growth can be ...